news

1/2/2024
pharmaand GmbH’s Rubraca®▼ (rucaparib) approved in the United Kingdom as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
1/2/2024
pharmaand GmbH and GHN Pharma Nordic AB Announce Collaboration Extension and Expansion
17/1/2024
pharma& Acquires the Global Rights to satraplatin from Dayton Therapeutics
20/11/2023
European Commission Approves pharmaand GmbH’s Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer
16/10/2023
pharmaand GmbH Receives Positive CHMP Opinion for Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer

read more in our news archive